Total Payments
$368,287
2024 Payments
$40,463
Companies
36
Transactions
756
Medicare Patients
906
Medicare Billing
$153,683
Payment Breakdown by Category
Other$221,630 (60.2%)
Consulting$67,780 (18.4%)
Research$38,344 (10.4%)
Travel$24,185 (6.6%)
Food & Beverage$16,063 (4.4%)
Education$285.47 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $190,290 | 100 | 51.7% |
| Consulting Fee | $67,780 | 21 | 18.4% |
| Unspecified | $38,344 | 9 | 10.4% |
| Honoraria | $31,340 | 15 | 8.5% |
| Travel and Lodging | $24,185 | 131 | 6.6% |
| Food and Beverage | $16,063 | 472 | 4.4% |
| Education | $285.47 | 8 | 0.1% |
Payments by Type
General
$329,943
747 transactions
Research
$38,344
9 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Kyowa Kirin, Inc. | $135,941 | 120 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $79,962 | 157 | $0 (2024) |
| Neurocrine Biosciences, Inc. | $53,195 | 55 | $0 (2024) |
| Acorda Therapeutics, Inc | $42,846 | 70 | $0 (2024) |
| Adamas Pharmaceuticals, Inc. | $27,252 | 36 | $0 (2021) |
| Sunovion Pharmaceuticals Inc. | $11,445 | 18 | $0 (2022) |
| Amneal Pharmaceuticals LLC | $7,710 | 18 | $0 (2024) |
| Medtronic, Inc. | $2,121 | 33 | $0 (2024) |
| ACADIA Pharmaceuticals Inc | $2,109 | 70 | $0 (2024) |
| Boston Scientific Corporation | $1,292 | 8 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $40,463 | 158 | Kyowa Kirin, Inc. ($21,331) |
| 2023 | $21,713 | 95 | Teva Pharmaceuticals USA, Inc. ($9,734) |
| 2022 | $58,625 | 118 | Kyowa Kirin, Inc. ($46,005) |
| 2021 | $66,058 | 102 | Kyowa Kirin, Inc. ($50,118) |
| 2020 | $49,483 | 61 | Neurocrine Biosciences, Inc. ($15,664) |
| 2019 | $97,290 | 127 | Acorda Therapeutics, Inc ($40,439) |
| 2018 | $29,444 | 82 | Teva Pharmaceuticals USA, Inc. ($12,403) |
| 2017 | $5,211 | 13 | Teva Pharmaceuticals USA, Inc. ($4,955) |
All Payment Transactions
756 individual payment records from CMS Open Payments — Page 1 of 31
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Boston Scientific Corporation | — | Food and Beverage | In-kind items and services | $166.05 | General |
| Category: General - DBS_NMD | ||||||
| 12/12/2024 | Merz Pharmaceuticals, LLC | Xeomin (Biological) | Food and Beverage | In-kind items and services | $21.11 | General |
| Category: Musculoskeletal | ||||||
| 12/11/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $28.20 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 12/10/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $20.84 | General |
| Category: Neuropsychiatry | ||||||
| 12/10/2024 | Abbott Laboratories | INFINITY (Device) | Food and Beverage | In-kind items and services | $8.86 | General |
| Category: Neuromodulation | ||||||
| 12/10/2024 | Kyowa Kirin, Inc. | Nourianz (Drug) | Food and Beverage | In-kind items and services | $4.91 | General |
| Category: Adenosine A2A Receptors | ||||||
| 12/04/2024 | Kyowa Kirin, Inc. | Nourianz (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,480.00 | General |
| Category: Adenosine A2A Receptors | ||||||
| 12/04/2024 | Kyowa Kirin, Inc. | Nourianz (Drug) | Travel and Lodging | Cash or cash equivalent | $67.07 | General |
| Category: Adenosine A2A Receptors | ||||||
| 12/04/2024 | Kyowa Kirin, Inc. | Nourianz (Drug) | Travel and Lodging | Cash or cash equivalent | $61.25 | General |
| Category: Adenosine A2A Receptors | ||||||
| 12/04/2024 | Kyowa Kirin, Inc. | Nourianz (Drug) | Travel and Lodging | Cash or cash equivalent | $45.50 | General |
| Category: Adenosine A2A Receptors | ||||||
| 12/04/2024 | Kyowa Kirin, Inc. | Nourianz (Drug) | Travel and Lodging | Cash or cash equivalent | $44.49 | General |
| Category: Adenosine A2A Receptors | ||||||
| 12/04/2024 | Kyowa Kirin, Inc. | Nourianz (Drug) | Food and Beverage | Cash or cash equivalent | $3.49 | General |
| Category: Adenosine A2A Receptors | ||||||
| 11/19/2024 | Kyowa Kirin, Inc. | Nourianz (Drug) | Food and Beverage | In-kind items and services | $7.35 | General |
| Category: Adenosine A2A Receptors | ||||||
| 11/18/2024 | Kyowa Kirin, Inc. | Nourianz (Drug) | Travel and Lodging | In-kind items and services | $93.48 | General |
| Category: Adenosine A2A Receptors | ||||||
| 11/18/2024 | Kyowa Kirin, Inc. | Nourianz (Drug) | Travel and Lodging | In-kind items and services | $93.48 | General |
| Category: Adenosine A2A Receptors | ||||||
| 11/18/2024 | Merz Pharmaceuticals, LLC | Xeomin (Biological) | Food and Beverage | In-kind items and services | $22.69 | General |
| Category: Musculoskeletal | ||||||
| 11/14/2024 | Abbott Laboratories | INFINITY (Device) | Food and Beverage | In-kind items and services | $86.22 | General |
| Category: Neuromodulation | ||||||
| 11/11/2024 | Medtronic, Inc. | — | Travel and Lodging | In-kind items and services | $31.47 | General |
| 11/06/2024 | Abbott Laboratories | INFINITY (Device) | Food and Beverage | In-kind items and services | $22.29 | General |
| Category: Neuromodulation | ||||||
| 11/06/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $20.53 | General |
| 11/06/2024 | Genentech USA, Inc. | Ocrevus Zunovo (Biological) | Food and Beverage | In-kind items and services | $13.98 | General |
| Category: Immunology | ||||||
| 11/06/2024 | Abbott Laboratories | INFINITY (Device) | Food and Beverage | In-kind items and services | $4.23 | General |
| Category: Neuromodulation | ||||||
| 11/06/2024 | Abbott Laboratories | INFINITY (Device) | Food and Beverage | In-kind items and services | $3.86 | General |
| Category: Neuromodulation | ||||||
| 11/05/2024 | Kyowa Kirin, Inc. | Nourianz (Drug) | Food and Beverage | In-kind items and services | $10.98 | General |
| Category: Adenosine A2A Receptors | ||||||
| 11/04/2024 | ABBVIE INC. | VYALEV (Drug) | Food and Beverage | In-kind items and services | $24.34 | General |
| Category: NEUROSCIENCE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF VALBENAZINE FOR THE TREATMENT OF CHOREA ASSOCIATED WITH HUNTINGTON DISEASE | Neurocrine Biosciences, Inc. | $38,344 | 9 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 172 | 388 | $129,875 | $35,455 |
| 2022 | 5 | 193 | 416 | $131,196 | $37,227 |
| 2021 | 4 | 254 | 490 | $122,217 | $44,495 |
| 2020 | 6 | 287 | 445 | $139,983 | $36,507 |
Total Patients
906
Total Services
1,739
Medicare Billing
$153,683
Procedure Codes
20
All Medicare Procedures & Services
20 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 104 | 221 | $100,776 | $27,566 | 27.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 19 | 19 | $9,101 | $3,243 | 35.6% |
| 95984 | Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, each additional 15 minutes with qualified health professional | Office | 2023 | 13 | 60 | $9,720 | $1,992 | 20.5% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 23 | 58 | $4,698 | $1,520 | 32.4% |
| 95983 | Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, first 15 minutes with qualified health professional | Office | 2023 | 13 | 30 | $5,580 | $1,134 | 20.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 111 | 222 | $100,328 | $28,520 | 28.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 20 | 20 | $9,580 | $3,325 | 34.7% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2022 | 40 | 92 | $7,452 | $2,282 | 30.6% |
| 95984 | Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, each additional 15 minutes with qualified health professional | Office | 2022 | 11 | 59 | $9,558 | $2,168 | 22.7% |
| 95983 | Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, first 15 minutes with qualified health professional | Office | 2022 | 11 | 23 | $4,278 | $932.21 | 21.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 132 | 279 | $98,296 | $36,668 | 37.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 25 | 25 | $11,975 | $4,282 | 35.8% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2021 | 53 | 121 | $9,801 | $3,290 | 33.6% |
| 96127 | Brief emotional or behavioral assessment | Office | 2021 | 44 | 65 | $2,145 | $255.36 | 11.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 112 | 203 | $91,955 | $21,048 | 22.9% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 35 | 35 | $16,765 | $5,206 | 31.1% |
| 99354 | Prolonged office or other outpatient service first hour | Office | 2020 | 39 | 47 | $13,630 | $4,929 | 36.2% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 29 | 34 | $7,761 | $2,718 | 35.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 27 | 29 | $6,670 | $2,308 | 34.6% |
| 96127 | Brief emotional or behavioral assessment | Office | 2020 | 45 | 97 | $3,201 | $297.64 | 9.3% |
About Dr. Raja Mehanna, MD
Dr. Raja Mehanna, MD is a Neurology healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/08/2009. The National Provider Identifier (NPI) number assigned to this provider is 1184861502.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Raja Mehanna, MD has received a total of $368,287 in payments from pharmaceutical and medical device companies, with $40,463 received in 2024. These payments were reported across 756 transactions from 36 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($190,290).
As a Medicare-enrolled provider, Mehanna has provided services to 906 Medicare beneficiaries, totaling 1,739 services with total Medicare billing of $153,683. Data is available for 4 years (2020–2023), covering 20 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Houston, TX
- Active Since 01/08/2009
- Last Updated 08/02/2016
- Taxonomy Code 2084N0400X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1184861502
Products in Payments
- NOURIANZ (Drug) $109,991
- AUSTEDO (Drug) $62,693
- INBRIJA (Drug) $42,467
- GOCOVRI (Drug) $27,252
- Nourianz (Drug) $25,950
- Austedo XR (Drug) $16,328
- RYTARY (Drug) $7,680
- KYNMOBI (Drug) $7,172
- Ongentys (Drug) $4,814
- NUPLAZID (Drug) $1,784
- INFINITY (Device) $927.50
- ACTIVA (Device) $805.09
- SD809-TD (Drug) $562.95
- INGREZZA (Drug) $540.04
- PERCEPT PC BRAINSENSE (Device) $511.59
- BOTOX (Biological) $478.01
- DUOPA (Drug) $382.27
- XEOMIN (Biological) $326.19
- DISEASE EDUCATION (Drug) $325.00
- VERCISE (Device) $163.65
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Houston
William Ondo, M.d, M.D
Neurology — Payments: $1.5M
Neurology $1.5M
Dr. Annette Howard, Md, MD
Neurology — Payments: $1.2M
Neurology $1.2M
Paul Schulz, M.d, M.D
Neurology — Payments: $943,067
Neurology $943,067
Amit Verma, Md, MD
Neurology — Payments: $817,815
Neurology $817,815
Dr. Randolph Evans, Md, MD
Neurology — Payments: $715,948
Neurology $715,948
Dr. John Volpi, Md, MD
Neurology — Payments: $569,676
Neurology $569,676